Phase 1 Haemophilia Trial, Recruiting NCT07220564 Sponsor: Novo Nordisk A/S Condition: Haemophilia
Back to Haemophilia

Phase 1 Haemophilia Trial, Recruiting

NCT07220564
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are male
  • People who are between 18 and 64 years old (inclusive) at the time of signing the consent form
  • People who weigh 45 kilograms or more
  • People who have been diagnosed with congenital haemophilia A (meaning they were born with it) with a factor VIII activity level of 15% or lower, with or without inhibitors (antibodies that block factor VIII treatment), based on their medical records

Who may not be able to join:

  • People who are currently using or have recently used any preventative (prophylactic) treatment for haemophilia A within a specific timeframe based on how long that medication stays in the body
  • People whose body mass index (a measure of body weight relative to height) is 30 or higher
  • People who have a higher-than-normal risk of blood clots — for example, if they or a close blood relative have had an unexplained deep vein thrombosis (a blood clot in a deep vein)
  • People who have any signs or a confirmed diagnosis of a disease involving blood clots in the veins or arteries
  • People who have any known blood clotting disorder other than haemophilia A
  • People who are currently receiving or planning to start immune tolerance induction therapy (a treatment designed to reduce the body's resistance to factor VIII)
  • People who have significant digestive system conditions that may affect how the body absorbs medications or nutrients, as determined by the trial investigator

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Phone: (+1) 866-867-7178

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
23 October 2025
Est. completion
5 February 2027

Where this trial is recruiting

🇦🇹 Austria 🇧🇪 Belgium 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇵🇱 Poland 🇵🇹 Portugal 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Number of treatment emergent adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov